{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Heartland Daily Podcast","title":"Should This Non-mRNA Vaccine Have Been Authorized Early in the Pandemic? (Guest: Raymond March)","html":"","width":"100%","height":180,"duration":862,"description":"The FDA recently gave emergency use authorization (EUA) to the Novavax COVID-19 vaccine. Unlike the vaccines Americans received as a result of Operation Warp Speed, Novavax is not an mRNA vaccine. It was bypassed for EUA early in the pandemic because of a decision to put all resources into mRNA vaccines as it was thought this provided the best approach to get a vaccine out quickly.\r\n\r\n\r\nOur guest today, Raymond March, a research fellow for the Independent Institute and assistant professor of agribusiness and applied economics at North Dakota State University, says this was a costly mistake. In an op-ed, March explains why it took so long for the U.S. to get access to the Novavax vaccine. March discusses Novavax’s different technology, the history of protein-based vaccines, and the dangers in using a one-size-fits-all approach when dealing with a public health threat. \r\n \r\n\r\nNovavax Authorization: https://ir.novavax.com/2022-10-19-U-S-FDA-Grants-Emergency-Use-Authorization-for-Novavax-COVID-19-Vaccine,-Adjuvanted-as-a-Booster-for-Adults\r\n\r\nOp-ed: https://blog.independent.org/2022/08/12/take-so-long-novavax-vaccine/","thumbnail_url":"https://img.transistorcdn.com/2xLxMmPe28MnonUa9AciVxMi_Bu3CavKGZzqhK99mjE/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzM2NzQzLzE2Njk4/Mzk1OTktYXJ0d29y/ay5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}